Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label expansions, and commercial launches across oncology, cardiovascular, bone health, and inflammation, reflecting the company’s strategy of science-led innovation and patient-focused execution. The year positions Amgen for sustained growth and impact in 2026.
Oncology Portfolio: Precision Therapy Expansion
Blincyto® — Acute Lymphoblastic Leukemia (ALL)
Condition: Relapsed or refractory B-cell precursor ALL
In 2025, Blincyto expanded into new geographies with regulatory approvals supporting earlier-line treatment.
Strategic Impact:
Blincyto reinforces Amgen’s precision oncology leadership and contributes to specialty therapy growth.
Lumakras® — KRAS G12C-Mutated Non-Small Cell Lung Cancer
Condition: KRAS G12C-positive NSCLC
Lumakras received label expansions in 2025, broadening patient access and reinforcing Amgen’s targeted therapy portfolio.
Cardiovascular and Metabolic Portfolio
Repatha® — Hypercholesterolemia
Condition: High cholesterol (familial hypercholesterolemia and atherosclerotic cardiovascular disease)
Repatha achieved expanded approvals and increased uptake in 2025, strengthening Amgen’s presence in cardiovascular risk management.
Omecamtiv Mecarbil — Heart Failure
Condition: Chronic heart failure with reduced ejection fraction
Following 2025 approvals, Amgen advanced Omecamtiv Mecarbil commercial launches in key markets.
Bone Health Portfolio
Evenity® — Osteoporosis
Condition: Postmenopausal osteoporosis
Evenity received expanded label approval and launch initiatives in 2025, supporting growth in the rare and specialty bone health segment.
Inflammation Portfolio
Otezla® — Psoriasis and Psoriatic Arthritis
Condition: Moderate-to-severe plaque psoriasis and psoriatic arthritis
Otezla maintained strong uptake in 2025, supported by label expansions and market access programs.
Strategic Impact:
The inflammation franchise complements Amgen’s oncology, cardiovascular, and bone health portfolio, contributing to diversified revenue streams.
Digital, AI, and R&D Enablement
Amgen leveraged AI and digital platforms in 2025 to:
- Accelerate drug discovery and predictive clinical modeling
- Optimize patient selection for trials and commercial launches
- Enhance data-driven decision-making across R&D and commercialization
Strategic Impact:
AI integration supports faster development timelines, improved trial efficiency, and precise commercial execution.
Looking Ahead: 2026 and Beyond
Amgen enters 2026 with:
- A strengthened oncology and cardiovascular pipeline
- Expanded bone health and inflammation franchises
- AI-enabled insights driving portfolio prioritization and innovation
The company’s 2025 approvals and launches lay the foundation for sustained growth, patient impact, and market leadership in 2026.
Conclusion
Amgen’s 2025 execution demonstrates portfolio expansion, innovation leadership, and patient-focused strategy. With key approvals and launches across oncology, cardiovascular, bone health, and inflammation, the company is positioned to deliver clinical impact and long-term growth well into 2026.
By
